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Abstract
Data sharing from clinical trials is one way of promoting fair and transparent conduct of clinical trials. It would
maximise the use of data and permit the exploration of additional hypotheses. On the other hand, the quality
of secondary analyses cannot always be ascertained, and it may be unfair to investigators who have expended
resources to collect data to bear the additional burden of sharing. As the discussion on the best modalities of
sharing data evolves, some of the practical issues that may arise need to be addressed. In this paper, we discuss
issues which impede the use of data even when sharing should be possible: (1) multicentre studies requiring
consent from all the investigators in each centre; (2) remote access platforms with software limitations and Internet
requirements; (3) on-site data analysis when data cannot be moved; (4) governing bodies for data generated in
one jurisdiction and analysed in another; (5) using programmatic data collected as part of routine care; (6) data
collected in multiple languages; (7) poor data quality. We believe these issues apply to all primary data and cause
undue difficulties in conducting analysis even when there is some willingness to share. They can be avoided by
anticipating the possibility of sharing any clinical data and pre-emptively removing or addressing restrictions that
limit complete sharing. These issues should be part of the data sharing discussion.
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Background
In the past few years, we have experienced an upsurge in
calls for complete sharing of data from clinical trials and
other primary studies. Many important steps have been
taken in this direction, including the opening of data
sharing repositories [1], mandatory sharing of data by
journals as proposed by the International Committee of
Medical Journal Editors (ICMJE) [2], pharmaceutical
companies making their data available [3] and published
guidance on how to share data [4].
Data sharing comes with the advantages of maximising
the use of data collected as an increased tribute to study
participants, exploring further bits of evidence that might
not have been part of the initial investigation and provid-
ing the ability to merge data from individual studies [5, 6].
It also serves to maintain integrity in data analysis in a
situation where there is a concern about a conflict of
interest [6]. In addition, data sharing can reduce duplica-
tion of research efforts and costs as well as patient expos-
ure to potentially harmful interventions in new trials, and
it can enhance the decision-making process from regula-
tory, guideline and clinical perspectives [4].
The ideal of complete data sharing is hampered by
many concerns and challenges. Some concerns include
the misinterpretation of the data by a secondary user,
inappropriate merging of heterogeneous datasets and
’parasitic’ data use — with the sole aim of stealing re-
search productivity [5]. There is also the risk of breaches
of confidentiality and the burden of administrative and
financial costs associated with data sharing [4]. More so,
if data are shared immediately after a trial is completed,
there is a risk of the original investigators not having
sufficient time to publish the primary results of the trial
and any additional secondary analyses [7].
While the focus of data sharing relates to clinical trials,
there are other methodologies for which data sharing may
be beneficial. A good example is the use of a new pharma-
ceutical drug in development that has been approved for a
compassionate care programme. Data collected within
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such a programme will be useful in providing evidence on
the merits of the drug.
In this paper, we share the experiences of the Biostatistics
Unit of The Research Institute at St Joseph’s Healthcare
Hamilton. We describe situations that cause delays in the
data acquisition process. Details on the actual studies in
which these issues occurred are not revealed.
Approval from all authors is required for some
multicentre studies
In certain instances, it may be challenging to obtain data
from a multicentre study because all the principal investi-
gators (PIs) of each site are expected to provide consent.
This can lead to enormous delays in the data sharing
process, especially in multinational trials including many
sites. This problem can be resolved by anticipating data
sharing requirements prior to initiating the study, so that
the individual PIs can consent to the possibility of sharing
their data. Seeking consent from each individual site is
akin to looking up patients to request their consent for
secondary data analysis after a trial is complete. It renders
the process unduly onerous and should be discouraged.
Steps should be taken at the outset of the study to antici-
pate future data sharing.
Remote platforms
Data sharing via remote platforms offers researchers the
possibility of analysing a dataset from a remote desktop
through a secure connection without the possibility of
downloading the data. With this approach, the reposi-
tory is a 'trusted middle-man’. While this ensures the
safety of the data and encourages transparency, it causes
several hindrances. First, a strong and reliable Internet
connection is required to stay connected to the secure
platform. Second, any data merging will require that any
other datasets be put onto that secure platform, even
though typical data sharing agreements preclude sharing
of data with a third party. Finally, remote platforms may
not have all the software an analyst would require to
clean, prepare and analyse the data.
Data analysis on site
Requiring that data be analysed on site implies that
the analyst should be physically present at a specific
terminal in a building to have access to the data.
Long-distance travel, accommodation and travel risk
are some of the reasons why this kind of data sharing
is not pragmatic. In addition, one would have to phys-
ically transport other datasets to this specific site. It
also creates challenges for re-analyses and further ex-
plorations of data.
Governing bodies
Given that the legislation on data varies in different parts
of the world, standards should be set with regard to
which jurisdiction is responsible for implementing the
terms of data sharing agreements. Understandably, each
party would prefer to be governed by the legislations of
the jurisdiction in which they reside. This is often not
acceptable to second parties.
Securing ethics approval for programmatic data
If one requests data that have not been collected as part
of research (therefore, formal consent was not obtained)
but rather as part of routine care, who is responsible for
securing ethics approval for data sharing? It may be
unfair to request that the custodians of the data initiate
the potentially burdensome process of getting ethics
approval to share data, but on the other hand it would
also be challenging to prepare, submit and follow up a
request for ethics approval in a distant country, espe-
cially if there are language differences.
Data collected in multiple languages
For some multicentre studies, data text fields are com-
pleted in the local language and require considerable
time and effort to translate. Analysts may find them-
selves having to deal with three or four languages in the
same dataset. At the very minimum, data should be col-
lected and coded in only one language.
Data quality
Given the time and effort required to clean and prepare
a dataset for analysis, investigators often share data that
have not been cleaned. This may lead to incorrect values
being used for analysis and, consequently, potentially
misleading results. We believe the persons who created
the dataset are the best equipped to clean it, as they have
a better understanding of the context of the study, why
values may be missing and how best to replace them.
Conclusion
Data collected for research or otherwise should have
data sharing arrangements in place prior to collecting
the data for other potential users. Remotely provided
data or data requiring travel are not completely shared,
in our opinion, and place undue duress on the analyst.
The instances described above are situated somewhere
along the continuum of absolutely no data shared, on
the one hand, to a clean and ready-for-analysis dataset
on the other. We have enormous appreciation for the
efforts researchers are making for others to be able to
access and use their data, but we believe more can be
done. Now is the time to seriously consider the practical
modalities of data sharing, not only for clinical trials, but
for all clinical studies.
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